Drug intelligence / Profile preview

AFX-1099

Development stage: Unknown
Lead developer: Afecta Pharmaceuticals
Modality: Small Molecules
Administration: Intratumoral

Overview

AFX-1099 is a small molecule therapeutic candidate being developed by Afecta Pharmaceuticals for the treatment of glioblastoma. It is currently in Phase 1 clinical development. Afecta Pharmaceuticals focuses on developing innovative therapies by leveraging its expertise in drug delivery and metabolic reprogramming to address high-grade gliomas and other cancers. While specific details regarding its molecular target and chemical structure are not widely disclosed in public clinical databases, it is part of a pipeline that emphasizes targeting the metabolic vulnerabilities of cancer cells.

Beyond the preview

Go deeper on AFX-1099.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFX-1099.

Explore the full profile